Heart failure drug JARDIANCE® passes Long-Term safety check in japan
NCT ID NCT05262764
First seen Apr 04, 2026
Summary
This completed study monitored 1200 Japanese patients with chronic heart failure who took JARDIANCE® (empagliflozin) daily for a long time. Researchers tracked side effects like low blood sugar, dehydration, and kidney problems, as well as deaths and hospitalizations. The goal was to see how safe and effective the drug is in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (JARDIANCE®)
What this could lead to
If results are positive, this could confirm that empagliflozin is safe and effective for long-term use in Japanese patients with chronic heart failure.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.